Menu Search
Equities

Aurora Spine Corp

ASAPF:QBB

Aurora Spine Corp

Actions
Health CareMedical Equipment and Services
  • Price (USD)0.3179
  • Today's Change0.00 / 0.00%
  • Shares traded500.00
  • 1 Year change-3.08%
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024 18:33 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Aurora Spine Corporation is a designer and manufacturer of medical devices. The Company is engaged in the development and distribution of minimally invasive, interspinous fusion systems and devices. It offers a range of devices specifically designed to address cervical spine conditions and restore optimal functionality. Its Cervical product line includes apollo, Discovery, and DEXA-C. The apollo Anterior Cervical Plate system is comprised of cervical plates and bone screws constructed of titanium alloy as described by ASTM F136. Discovery is its Spine's invasive cervical interbody fusion system. The DEXA-C is crafted to mimic the lattice structure of cancellous bone in humans while maintaining a comparable modulus of elasticity. The Company has established a physician training program through national and regional cadaver labs.

  • Revenue in CAD (TTM)23.66m
  • Net income in CAD-889.47k
  • Incorporated2013
  • Employees13.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.